A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase IIIb, multicenter, open-label trial of daily oral Tarceva in patients with
advanced (inoperable Stage IIIb or IV) NSCLC who have progressed following standard
chemotherapy treatment.